Radio Munich talked with German Professor
Dr. Stefan Hockertz, is a biologist, pharmacologist and toxicologist, who has raised the alarm about a number of unanswered questions surrounding the current coronavirus crisis, challenging lockdowns, and also pharmaceutical interventions – specifically regarding ethics and safety of the new experimental mRNA vaccine. According the Dr Hockertz, lockdown have never been proven to work, and the rushed nature of new mRNA vaccine may pose an unnecessary risk for countless people. All this and more.
Dr. Stefan Hockertz was director and professor of the Institute for Experimental and Clinical Toxicology at the University Medical Center Hamburg Eppendorf from 2003 – 2004, and was on the board of directors at Fraunhofer Institute for Toxicology and Environmental Medicine in Hamburg from 1995 – 2002. From 1986 to 2001 he was a researcher at the Fraunhofer Society in Hanover, and has also worked at the University of Hanover. He completed his f
Patients with Chronic Rare Conditions Feel Unsupported
Share
Rare Daily Staff
Patients with chronic rare disease do not feel they receive adequate support in a range of areas for their psycho-social wellbeing, according to the first study to assess supportive care needs quantitatively and qualitatively among this population.
The study, conducted by researchers at the University Medical Center Hamburg-Eppendorf and published in the
, is the first study aimed at investigating supportive care needs in patients with different rare chronic diseases across a broad range of areas including health system and information, physical needs, patient care, sexuality, and psychological needs.
The results were based on responses from 304 participants at least 16 years of age with 81 different rare diseases. More than 80 percent of the respondents were female. The study relied on both a quantifiable survey as well as open-ended questions. It used a survey of supportive care nee
E-Mail
Amsterdam, NL, January 26, 2021 - With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson s disease (PD). According to results of a survey of PD patients in Germany in the
Journal of Parkinson s Disease, over 8% of patients with PD reported using cannabis products and more than half of those users (54%) reported a beneficial clinical effect.
Cannabis products containing THC (tetrahydrocannabinol, the main psychoactive compound of cannabis) can be prescribed in Germany when previous therapies are unsuccessful or not tolerated, and where cannabis can be expected with not a very unlikely chance to relieve disabling symptoms. CBD (pure cannabidiol, derived directly from the hemp plant, a cousin of the marijuana plant) is available without a prescription from pharmacies and on the internet.
DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilities
News provided by
Share this article
Share this article
PFÄFFIKON, Switzerland, Jan. 19, 2021 /PRNewswire/ DiNAQOR, a gene therapy platform company, today announced that it has acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company. Financial terms of the transaction were not disclosed.
EHT Technologies was founded in 2015 based upon research on human induced pluripotent stem cells (hiPSC) at the University Medical Center Hamburg
-Eppendorf. Cardiomyocytes derived from hiPSC are an innovative research technology for cardiac drug development programs. Engineered heart tissues are three-dimensional, hydrogel-based muscle constructs that can be generated from isolated heart cells of chicken, rat, mouse, human embryonic stem cells and hiPSC. Proof-of-concept studies have shown that EHT can be transduced efficiently with adeno-associated